57 Altered Biomechanics Drives Outcome in Breast Cancer: A New Avenue for Oncology Biomarkers

Research into breast cancer has identified biomechanical drivers as a key factor in poor patient outcomes. By analyzing two clinical cohorts, researchers found that aggressive mechanical phenotypes often occur in spatial regions of hypoxia-driven epithelial-to-mesenchymal transition, which can drive tumor invasion and resistance to treatment.

The study used a dual approach to resolve the molecular drivers of these altered mechanics. This method combined spatial proteomics profiles with the mechanical functional phenotypes of breast cancer to identify biomarkers that influence long-term outcomes.

How do biomechanical phenotypes affect breast cancer outcomes?

Biomechanical phenotypes drive invasion and treatment resistance in solid tumors. According to the study, there is a nonlinearity between molecular biology and these mechanical states.

This means different tumor microenvironments, characterized by different genomics or proteomics, can result in similar mechanical phenotypes. These similar phenotypes then drive the same aggressive outcomes regardless of the initial molecular difference.

Did You Know? The first patient cohort included 700 primary breast cancer samples from 113 women with more than 20 years of follow-up.

What methods were used to identify these biomarkers?

Researchers utilized two separate clinical cohorts. The first cohort employed a custom imaging mass cytometry panel of 65 biomarkers to analyze cancer signaling, immune cells, and stromal structures.

Integrative Oncology at the Breast Center Kliniken Essen Mitte (Germany)

This group included 64 patients alive 12 years after diagnosis and 49 patients lost to breast cancer deaths. These patients had received treatments including surgery, radiation, chemotherapy, and endocrine therapy.

The second cohort involved patients at the Breast Clinic in Basel, Switzerland. Researchers used the ARTIDIS device on fresh samples collected during routine clinical workflows to identify nanomechanical phenotypes.

Expert Insight: Samantha Carter notes that the nonlinearity between a tumor’s proteomic profile and its mechanical phenotype suggests that focusing solely on genomics may miss how a tumor physically behaves. Identifying these biomechanical signatures could potentially highlight risks that traditional molecular profiling might overlook.

What could this mean for future breast cancer research?

The identification of hypoxia-driven epithelial-to-mesenchymal transition as a driver of poor outcomes may lead to new ways of stratifying patients. A new three-parameter quantitative metric used in the study could possibly be applied to further refine survival analysis.

Future efforts may focus on how these tumor-immune-stromal spatial patterns vary in scale. This could lead to a deeper mechanistic interpretation of how altered biomechanics drive treatment resistance.

Frequently Asked Questions

What was the role of the ARTIDIS device in this research?
The ARTIDIS device was used on fresh samples from patients at the Breast Clinic in Basel, Switzerland, to identify altered nanomechanical phenotypes in breast cancer.

How many biomarkers were used in the imaging mass cytometry panel?
The researchers used a custom-developed panel consisting of 65 biomarkers to resolve cancer signaling, immune and stromal cells, and microenvironmental cues.

What biological signature was linked to aggressive mechanical phenotypes?
The study identified a strong biological signature in spatial regions of hypoxia-driven epithelial-to-mesenchymal transition.

How do you feel about the integration of mechanical physics into traditional cancer biology?